Supriya Lifescience Reports Q2 FY27 Results and Appoints COO
Supriya Lifescience Ltd · Outcome · 06 Nov 2026, 6:25 pm
Supriya Lifescience Reports Q2 FY27 Results and Appoints COO For the quarter ended 30th Sep'26, Supriya Lifescience reported standalone revenue from operations of ₹2,062.97 mn, up 3.2% YoY and 8.7% QoQ. Net profit declined 42.0% YoY to ₹292.50 mn from ₹504.27 mn in Q2 FY26, though it grew 21.7% QoQ. Total expenses increased to ₹1,708.11 mn from ₹1,342.40 mn YoY. H1 FY27 revenue reached ₹3,960.44 mn with net profit at ₹532.93 mn. Additionally, the board approved the appointment of Mr. Mangesh Vaze as Chief Operating Officer, effective 6th Nov'26.
Original exchange filing (PDF)
More announcements from Supriya Lifescience Ltd
- Earnings Call Transcript is enclosed herewith. · 13 Nov 2026
- Outcome of the Results Earning Call for Quarter and Half year ended September 30, 2026 is enclosed herewith. · 07 Nov 2026
- Press Release is enclosed herewith. · 07 Nov 2026
- Investor Presentation is enclosed for the Results Earnings Call for quarter and half year ended September 30, 2026. · 06 Nov 2026
- Change In Management - Appointment of Senior Management Personnel of the Company. · 06 Nov 2026
- Please find enclosed. · 06 Nov 2026
- Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held .... · 06 Nov 2026
- Enclosed herewith is the announcement under Regulation 30 of SEBI (LODR) Regulations, 2015. Kindly take the same on record. · 03 Nov 2026
